BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

741 related articles for article (PubMed ID: 25750269)

  • 21. Recent advances in therapy for glioblastoma.
    Clarke J; Butowski N; Chang S
    Arch Neurol; 2010 Mar; 67(3):279-83. PubMed ID: 20212224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs.
    von Neubeck C; Seidlitz A; Kitzler HH; Beuthien-Baumann B; Krause M
    Br J Radiol; 2015 Sep; 88(1053):20150354. PubMed ID: 26159214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contribution of low-molecular weight heparin addition to concomitant chemoradiotherapy in the treatment of glioblastoma multiforme.
    Zincircioglu SB; Kaplan MA; Isikdogan A; Cil T; Karadayi B; Dirier A; Kucukoner M; Inal A; Yildiz I; Aggil F; Donmez O; Urakci Z; Pekkolay Z; Firat U
    J BUON; 2012; 17(1):124-7. PubMed ID: 22517705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
    Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
    Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Towards tailored therapy of glioblastoma multiforme.
    Rekers NH; Sminia P; Peters GJ
    J Chemother; 2011 Aug; 23(4):187-99. PubMed ID: 21803695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.
    Halatsch ME; Schmidt U; Behnke-Mursch J; Unterberg A; Wirtz CR
    Cancer Treat Rev; 2006 Apr; 32(2):74-89. PubMed ID: 16488082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.
    Neagu MR; Reardon DA
    Curr Treat Options Oncol; 2015 Nov; 16(11):54. PubMed ID: 26454859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glioblastoma multiforme: evidence-based approach to therapy.
    Nicholas MK
    Expert Rev Anticancer Ther; 2007 Dec; 7(12 Suppl):S23-7. PubMed ID: 18076314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dendritic cell immunotherapy for glioblastoma.
    Polyzoidis S; Ashkan K
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):761-3. PubMed ID: 24850137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme.
    De Vleeschouwer S; Fieuws S; Rutkowski S; Van Calenbergh F; Van Loon J; Goffin J; Sciot R; Wilms G; Demaerel P; Warmuth-Metz M; Soerensen N; Wolff JE; Wagner S; Kaempgen E; Van Gool SW
    Clin Cancer Res; 2008 May; 14(10):3098-104. PubMed ID: 18483377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [New therapeutic options in therapy of glioblastoma multiforme].
    Lakomý R; Burkon P; Burkonová D; Jancálek R
    Klin Onkol; 2010; 23(6):381-7. PubMed ID: 21351415
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Safety of available immunotherapy for the treatment of glioblastoma.
    Farber SH; Elsamadicy AA; Atik AF; Suryadevara CM; Chongsathidkiet P; Fecci PE; Sampson JH
    Expert Opin Drug Saf; 2017 Mar; 16(3):277-287. PubMed ID: 27989218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment options for glioblastoma.
    Chamberlain MC
    Neurosurg Focus; 2006 Apr; 20(4):E19. PubMed ID: 16709025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting EGFRvIII for glioblastoma multiforme.
    Yang J; Yan J; Liu B
    Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Agenus cancer vaccine extends survival of GBM patients.
    Riedmann EM
    Hum Vaccin Immunother; 2014; 10(2):252-3. PubMed ID: 24963517
    [No Abstract]   [Full Text] [Related]  

  • 36. Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305).
    Shibui S; Narita Y; Mizusawa J; Beppu T; Ogasawara K; Sawamura Y; Kobayashi H; Nishikawa R; Mishima K; Muragaki Y; Maruyama T; Kuratsu J; Nakamura H; Kochi M; Minamida Y; Yamaki T; Kumabe T; Tominaga T; Kayama T; Sakurada K; Nagane M; Kobayashi K; Nakamura H; Ito T; Yazaki T; Sasaki H; Tanaka K; Takahashi H; Asai A; Todo T; Wakabayashi T; Takahashi J; Takano S; Fujimaki T; Sumi M; Miyakita Y; Nakazato Y; Sato A; Fukuda H; Nomura K
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):511-21. PubMed ID: 23228988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme.
    Ung N; Yang I
    J Neurooncol; 2015 Jul; 123(3):473-81. PubMed ID: 26070553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Personalized neoantigen vaccines: a glimmer of hope for glioblastoma.
    Londhe VY; Date V
    Expert Rev Vaccines; 2020 May; 19(5):407-417. PubMed ID: 32238056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Designer therapies for glioblastoma multiforme.
    Sathornsumetee S; Rich JN
    Ann N Y Acad Sci; 2008 Oct; 1142():108-32. PubMed ID: 18990124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of newly diagnosed glioblastoma multiforme: current state of the art and emerging therapeutic approaches.
    McMahon DJ; Gleeson JP; O'Reilly S; Bambury RM
    Med Oncol; 2022 Jun; 39(9):129. PubMed ID: 35716200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.